Literature DB >> 22855698

Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China.

Wei-Hui Sun1, Ming-Quan Song, Chang-Qing Jiang, Yong-Ning Xin, Jian-Lin Ma, Ying-Xun Liu, Lei Ma, Zhong-Hua Lin, Chang-Yan Li, Ling Liu, Mei Zhang, Lei-Lei Chu, Xiang-Jun Jiang, Qiang Wan, Lin Zhou, Rong Ren, Ling-Fang Meng.   

Abstract

AIM: To evaluate the effect of a 6 and 12 mo lifestyle modification intervention in nonalcoholic fatty liver diseases (NAFLD) in Chengyang District of Qingdao.
METHODS: Participants with NAFLD who had resided in Chengyang District for more than 5 years were enrolled in this study. After the 6 and 12 mo lifestyle modification intervention based on physical activity, nutrition and behavior therapy, parameters such as body weight, body mass index (BMI), waist circumference, serum alanine aminotransferase (ALT), aspartate aminotransferase values, serum cholesterol, triglycerides, fasting glucose, fasting insulin and visceral fat area (VFA), the liver-spleen ratio and the homeostasis model assessment of insulin resistance (HOMA-IR) were evaluated and compared between participants with and without the intervention.
RESULTS: Seven hundred and twenty-four participants were assigned to the lifestyle intervention group (LS) and 363 participants were assigned to the control group (CON). After the intervention, body weights in the LS group were significantly decreased compared to those in the CON group at 6 mo (11.59% ± 4.7% vs 0.4% ± 0.2%, P = 0.001) and at 12 mo (12.73% ± 5.6% vs 0.9% ± 0.3%, P = 0.001). Compared with the CON group, BMI was more decreased in the LS group after 6 and 12 mo (P = 0.043 and P = 0.032). Waist circumference was more reduced in the LS group than in CON (P = 0.031 and P = 0.017). After the 6 and 12 mo intervention, ALT decreased significantly in the LS group (P = 0.003 and P = 0.002). After 6 and 12 mo, the metabolic syndrome rate had decreased more in the LS group compared with the CON group (P = 0.026 and P = 0.017). After 12 mo, the HOMA-IR score decreased more obviously in the LS group (P = 0.041); this result also appeared in the VFA after 12 mo in the LS group (P = 0.035).
CONCLUSION: Lifestyle intervention was effective in improving NAFLD in both 6 and 12 mo interventions. This intervention offered a practical approach for treating a large number of NAFLD patients in the Chengyang District of Qingdao.

Entities:  

Keywords:  Lifestyle intervention; Non-alcoholic fatty liver disease; Obese

Year:  2012        PMID: 22855698      PMCID: PMC3409357          DOI: 10.4254/wjh.v4.i7.224

Source DB:  PubMed          Journal:  World J Hepatol


  21 in total

1.  Compendium of physical activities: an update of activity codes and MET intensities.

Authors:  B E Ainsworth; W L Haskell; M C Whitt; M L Irwin; A M Swartz; S J Strath; W L O'Brien; D R Bassett; K H Schmitz; P O Emplaincourt; D R Jacobs; A S Leon
Journal:  Med Sci Sports Exerc       Date:  2000-09       Impact factor: 5.411

2.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

3.  Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Roberto Padovani; Stefano Rodella; Roberto Tessari; Luciano Zenari; Christopher Day; Guido Arcaro
Journal:  Diabetes Care       Date:  2007-02-02       Impact factor: 19.112

Review 4.  Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal.

Authors:  Valerio Nobili; Arun J Sanyal
Journal:  J Gastroenterol       Date:  2011-10-08       Impact factor: 7.527

Review 5.  Current therapies for nonalcoholic fatty liver disease.

Authors:  A A Gossard; K D Lindor
Journal:  Drugs Today (Barc)       Date:  2011-12       Impact factor: 2.245

6.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.

Authors:  A J Sanyal; C Campbell-Sargent; F Mirshahi; W B Rizzo; M J Contos; R K Sterling; V A Luketic; M L Shiffman; J N Clore
Journal:  Gastroenterology       Date:  2001-04       Impact factor: 22.682

7.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

8.  Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men.

Authors:  Michihiko Shibata; Yasuyuki Kihara; Masashi Taguchi; Mitsuo Tashiro; Makoto Otsuki
Journal:  Diabetes Care       Date:  2007-07-31       Impact factor: 19.112

9.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.

Authors:  Kittichai Promrat; David E Kleiner; Heather M Niemeier; Elizabeth Jackvony; Marie Kearns; Jack R Wands; Joseph L Fava; Rena R Wing
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

10.  A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff.

Authors:  Noriko Oza; Yuichiro Eguchi; Toshihiko Mizuta; Eriko Ishibashi; Yoichiro Kitajima; Hiroko Horie; Michiko Ushirogawa; Takeko Tsuzura; Shunya Nakashita; Hirokazu Takahashi; Yasunori Kawaguchi; Yasutomo Oda; Ryuichi Iwakiri; Iwata Ozaki; Takahisa Eguchi; Naofumi Ono; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2009-09-01       Impact factor: 7.527

View more
  13 in total

Review 1.  Non-Alcoholic Fatty Liver Disease, an Overview.

Authors:  Asia Muhammad Nd
Journal:  Integr Med (Encinitas)       Date:  2019-04

2.  Nonalcoholic Steatohepatitis, Peroxisome Proliferator-Activated Receptors and Our Good Glitazar: Proof of the Pudding is in the Eating.

Authors:  Anil C Anand; Subrata K Acharya
Journal:  J Clin Exp Hepatol       Date:  2022-01-25

Review 3.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

4.  Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review.

Authors:  Maureen Whitsett; Lisa B VanWagner
Journal:  World J Hepatol       Date:  2015-08-08

5.  Cut-Off Values of Visceral Adiposity to Predict NAFLD in Brazilian Obese Adolescents.

Authors:  Ana Paula Grotti Clemente; Bárbara Dal Molin Netto; Aline di Piano Ganen; Lian Tock; Danielle Arisa Caranti; Marco Túlio de Mello; Sergio Tufik; Ana R Dâmaso
Journal:  J Nutr Metab       Date:  2013-12-07

6.  Modeling the natural history of fatty liver using lifestyle-related risk factors: Effects of body mass index (BMI) on the life-course of fatty liver.

Authors:  Mika Aizawa; Seiichi Inagaki; Michiko Moriyama; Kenichiro Asano; Masayuki Kakehashi
Journal:  PLoS One       Date:  2019-10-21       Impact factor: 3.240

7.  Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.

Authors:  Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas J G Chase; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Dominic Fritche; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-06-11

Review 8.  Lifestyle interventions for the treatment of non-alcoholic fatty liver disease.

Authors:  V Bradford; Jf Dillon; Mh Miller
Journal:  Hepat Med       Date:  2013-12-11

Review 9.  A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD.

Authors:  Newaz Hossain; Pushpjeet Kanwar; Smruti R Mohanty
Journal:  Gastroenterol Res Pract       Date:  2016-02-23       Impact factor: 2.260

10.  Nonalcoholic fatty liver disease remission in men through regular exercise.

Authors:  Takafumi Osaka; Yoshitaka Hashimoto; Masahide Hamaguchi; Takao Kojima; Akihiro Obora; Michiaki Fukui
Journal:  J Clin Biochem Nutr       Date:  2018-03-17       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.